Accéder au contenu
Merck
Toutes les photos(4)

Key Documents

SAB1400064

Sigma-Aldrich

Anti-CYP3A4 antibody produced in mouse

IgG fraction of antiserum, buffered aqueous solution

Synonyme(s) :

Anti-CP33, Anti-CP34, Anti-CYP3A, Anti-CYP3A3, Anti-HLP, Anti-MGC126680, Anti-NF-25, Anti-P450C3, Anti-P450PCN1

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

IgG fraction of antiserum

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Espèces réactives

human

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: 1 μg/mL

Numéro d'accès UniProt

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... CYP3A4(1576)

Description générale

Cytochrome P450 3A4 (CYP3A4), the ubiquitous cytochrome P450 (CYP) seen in the adult liver and intestine, belongs to the CYP3A subfamily. The CYP3A4 gene with 13 exons is located on human chromosome 7q22.1.

Immunogène

CYP3A4 (AAI01632.1, 1 a.a. ~ 503 a.a) full-length human protein.

Sequence
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA

Application

Anti-CYP3A4 antibody produced in mouse has been used in the immunohistochemical analysis (1:100) and immunofluorescence staining (1:200).

Actions biochimiques/physiologiques

Cytochrome P450 3A4 (CYP3A4) plays a key role in the metabolism of several antineoplastic drugs. It aids in the catalysis of a wide range of substrates. CYP3A4 can detoxify bile acids. CYP3A4 gene mutations can disrupt the metabolism of commonly used medications, resulting in harmful blood concentrations of drugs. Such CYP3A4 polymorphisms may also affect the detoxification of bile acid.

Forme physique

Solution in phosphate buffered saline, pH 7.4

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Human Pluripotent Stem Cell-Derived Organoids as a Model of Intestinal Xenobiotic Metabolism
Sasaki K, et al.
Stem cell investigation, 1-10 (2021)
Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro
Han M, et al.
Chemico-Biological Interactions, 109559-109559 (2021)
Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters
Lazar A, et al.
Handbook of Analytical Separations , 5, 321-354 (2004)
Hideaki Nitta et al.
Journal of clinical medicine, 13(13) (2024-07-13)
Background: Aggressive mature T-cell lymphoma (TCL) is a disease that carries a poor prognosis. Methods: We analyzed the expression of 22 tumor cell functional proteins in 16 randomly selected patients with TCL. Immunohistochemistry was performed in paraffin-embedded tumor tissue sections
Assessing rat liver-derived biomatrix for hepatic tissue engineering with human fetal liver stem cells
Xu B, et al.
advanced techniques in biology & medicine, 1(3), 00012-00012 (2016)

Articles

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique